1. Home
  2. ADV vs AUTL Comparison

ADV vs AUTL Comparison

Compare ADV & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Advantage Solutions Inc.

ADV

Advantage Solutions Inc.

HOLD

Current Price

$33.09

Market Cap

523.2M

ML Signal

HOLD

Logo Autolus Therapeutics plc

AUTL

Autolus Therapeutics plc

HOLD

Current Price

$1.90

Market Cap

596.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ADV
AUTL
Founded
1987
2014
Country
United States
United Kingdom
Employees
N/A
N/A
Industry
Business Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
523.2M
596.2M
IPO Year
2019
2025

Fundamental Metrics

Financial Performance
Metric
ADV
AUTL
Price
$33.09
$1.90
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
4
Target Price
$45.83
$8.50
AVG Volume (30 Days)
62.6K
2.3M
Earning Date
05-06-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$3,542,642,000.00
$10,120,000.00
Revenue This Year
$0.63
$80.32
Revenue Next Year
$0.45
$53.96
P/E Ratio
N/A
N/A
Revenue Growth
N/A
496.00
52 Week Low
$0.49
$1.18
52 Week High
$47.45
$2.58

Technical Indicators

Market Signals
Indicator
ADV
AUTL
Relative Strength Index (RSI) 48.07 41.17
Support Level $0.70 $1.37
Resistance Level $35.50 $2.07
Average True Range (ATR) 1.68 0.10
MACD 0.06 -0.07
Stochastic Oscillator 55.25 1.79

Price Performance

Historical Comparison
ADV
AUTL

About ADV Advantage Solutions Inc.

Advantage Solutions Inc provides outsourced sales, marketing, merchandising, sampling, and retailer support services to consumer packaged goods manufacturers and retailers across North America. Its services are designed to support distribution, retail execution, shopper engagement, and private brand development across both physical and digital commerce environments. The company serves various clients across grocery, mass, club, retail pharmacy, convenience, and other channels. It operates through three reportable segments: Branded Services, Experiential Services, and Retailer Services. The majority of the revenue is derived from the Experiential Services segment, which provides in-store and digital sampling programs, demonstrations, and experiential events for manufacturers and retailers.

About AUTL Autolus Therapeutics plc

Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8. Company's T cell programming technologies tailors therapies to address the specific disease targeting and introduce new programming modules into a patient's T cells to give those T cells improved properties to recognize target cells and overcome fundamental disease defense mechanisms.

Share on Social Networks: